(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
01 December 2022 (01.12.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/249060 A1

(51) International Patent Classification:
C07D 487/04 (2006.01) *A61K 31/519* (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:
PCT/IB2022/054850

(22) International Filing Date:
24 May 2022 (24.05.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/CN2021/096104
26 May 2021 (26.05.2021) CN
PCT/CN2022/085537
07 April 2022 (07.04.2022) CN


(71) Applicant: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, 4056 Basel (CH).

(72) Inventors: **BORDAS, Vincent**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **BRUN, Jvan**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **DECKER, Andrea**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **FUREGATI, Markus**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **GOGNIAT, Geoffrey**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **GONG, Wanben**; Suzhou Novartis Technical Development Co., Ltd., #18-1, Tonglian Road, Bixi Subdistrict, Changshu, Jiangsu 215537 (CN). **HAMON, Jacques**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **HINRICHS, Juergen Hans-Hermann**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **HOLZER, Philipp**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **LIMAM, Fatma**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **MOEBITZ, Henrik**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **NOCITO, Sandro**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **PLATTNER, Simone**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **SCHMIEDEBERG, Niko**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **SCHOEPFER, Joseph**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **SOTO, Jessica**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **STRANG, Ross**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **YAO, Shuping**; Suzhou Novartis Technical Development Co., Ltd., 18-1 Tonglian Road Bixi Subdistrict, Changshu, Jiangsu 215537 (CN). **YU, Huangchao**; Suzhou Novartis Technical Development Co., Ltd., #18-1, Tonglian Road, Bixi Subdistrict, Changshu, Jiangsu 215537 (CN). **ZECRI, Frédéric**; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **ZHANG, Sisi**; Suzhou Novartis Technical Development Co., Ltd., #18-1, Tonglian Road, Bixi Subdistrict, Changshu, Jiangsu 215537 (CN).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: TRIAZOLO-PYRIMIDINE ANALOGUES FOR TREATING DISEASES CONNECTED TO THE INHIBITON OF WERNER SYNDROME RECQ HELICASE (WRN)



(I)

(57) Abstract: The present invention provides a compound, or a pharmaceutically acceptable salt thereof, of formula (I): (I) wherein R_1, R_2, R_3, R_4, R_5, R_{26}, R_{27}, y, R, M, W, L, V, T, Y, J, K and A are as described herein, therapeutic uses of said compounds, uses of said compounds as research chemicals, a pharmaceutical composition and combinations comprising said compounds, and methods for manufacturing the compounds of the invention.

WO 2022/249060 A1

[Continued on next page]

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*